Skip to main content

Table 2 Characteristics of the study sample of patients stratified according to the eGFR

From: Heart rate variability and target organ damage in hypertensive patients

 

Normal eGFR (group 1)

Mild decreased eGFR (group 2)

Moderate decreased eGFR (group 3)

P Values

    

ANOVA or χ2

group 1 vs group 2

group 1 vs group 3

group 2 vs group 3

Age (years)

56 ± 11.5

63,0 ± 11.7

70.0 ± 9.4

<0.001

0.001

<0.001

0.05

Gender (male/female)

31/17

76/43

20/13

0.928

   

Family history of hypertension (yes/no)

25/23

69/50

19/14

0.778

   

Family history of stroke (yes/no)

11/37

22/97

6/27

0.790

   

Smokers (yes/ex/no)

13/8/27

8/27/7

27/75/21

0.379

   

Diabetes (yes/no)

5/43

11/108

4/29

0.883

   

Diastolic BP (mmHg)

73.2 ± 14.0

77.3 ± 11.5

73.0 ± 9.8

0.048

0.129

1

0.185

Systolic BP (mmHg)

124.5 ± 23.3

137.5 ± 20.0

130.2 ± 27.3

0.002

0.002

0.754

0.286

Pulse pressure (mmHg)

51.3 ± 14.1

60.1 ± 16.9

57.3 ± 23.3

0.014

0.010

0.396

1

Fasting blood glucose (mmHg)

99.7 ± 32.2

102.8 ± 20.0

106.7 ± 23.9

0.432

1

0.589

1

Total Cholesterol (mg/dl)

178.9 ± 36.4

187.7 ± 40.8

189.0 ± 45.8

0.395

0.610

0.817

1

BMI (kg/m2)

27.4 ± 5.2

28.1 ± 4.6

26.7 ± 3.5

0.261

1

1

0.379

Beta-blockers (yes/no)

15/33

41/78

11/22

0.924

   

Alphabeta-blockers (yes/no)

5/43

14/105

2/31

0.639

   

Alpha-blockers (yes/no)

3/45

8/111

5/28

0.252

   

Diuretics (yes/no)

17/31

49/70

21/12

0.03

   

ACE inhibitor (yes/no)

16/32

48/71

11/22

0.604

   

Dihydropyridine (yes/no)

12/36

30/89

10/23

0.826

   

eGFR (mL/min/1.73 m2)

101.9 ± 12.0

74.3 ± 8.8

50.6 ± 8.0

<0.001

<0.001

<0.001

<0.001

IMT (mm)

1.8 ± 0.76

2.23 ± 1.21

2.91 ± 2.85

0.007

0.282

0.005

0.81

Vascular abnormalities (no/ thickening/plaque)

33/6/9

91/13/15

28/3/2

0.502

   

LVMi g/m2

124.3 ± 26. 2

133.0 ± 32.3

130.4 ± 32.1

0.258

0.301

1

1

Left Ventricular hypertrophy (no/yes)

24/24

44/75

12/21

0.268

   
  1. Data are expressed as mean and standard deviation for continuous variables (i.e. age) and as number of patients per each group for categorical variables (i.e. gender).
  2. The p-values refer to ANOVA and post-hoc comparisons with Bonferroni corrections for continuous variables, to χ2 for categorical variables.
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us